Emergent data on the impact of tumor sidedness on treatment of metastatic colorectal cancer (mCRC) have important implications for clinical practice. This study determined whether online continuing medical education (CME) could improve oncologists' knowledge of the most current data supporting the use of available therapeutic options in left-vs right-sided tumors, and improve clinician competence in evidence-based selection and optimal use of epidermal growth factor receptor (EGFR) antibodies in clinical practice.
Emergent data on the impact of tumor sidedness on treatment of metastatic colorectal cancer (mCRC) have important implications for clinical practice. This study determined whether online continuing medical education (CME) could improve oncologists' knowledge of the most current data supporting the use of available therapeutic options in left-vs right-sided tumors, and improve clinician competence in evidence-based selection and optimal use of epidermal growth factor receptor (EGFR) antibodies in clinical practice. Mary is a 64-year-old patient who has been receiving treatment with cetuximab for mCRC. She is responding well to therapy but has developed grade 2 skin rash. You inform her that this side effect has been observed with this agent but that you will manage the rash. Patient Case: James is a 66-year-old male who was recently diagnosed with mCRC. The primary tumor is located on the left side and was found to be EGFR RAS WT. His ECOG performance status is 1 and he has no significant comorbidities. He comes to your clinic to discuss potential retreatment options.
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Question: Based on recent data, which of the following targeted therapies in combination with FOLFOX or FOLFIRI would you recommend to this patient?
Answers:
A. Cetuximab .071
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